Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC patients

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 11145-11156

  Yu, Dangfan ^a   Du, Kaiqi ^a   Liu, Taifeng ^a   Chen, Guojun ^a  

^a Zhejiang Provincial Corps Hospital   (China)

Author keywords

CA125; Lung cancer; NSE; SCC; Tumor marker

Indexed keywords

CA 125 ANTIGEN; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; ENOLASE; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

AGED; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878444832     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140611145     Document Type: Article

References (36)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
2. Govindan, R.; Bogart, J.; Vokes, E.E. Locally advanced non-small cell lung cancer: The past, present, and future. J. Thorac. Oncol. 2008, 3, 917-928.
3. Miller, Y.E. Pathogenesis of lung cancer: 100 year report. Am. J. Respir. Cell Mol. Biol. 2005, 33, 216-223.
4. Barak, V.; Holdenrieder, S.; Nisman, B.; Stieber, P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark. 2010, 6, 191-196.
5. Holdenrieder, S.; Nagel, D.; Stieber, P. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomark. 2010, 6, 179-190.
6. Jorgensen, L.G.; Hansen, H.H.; Cooper, E.H. Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur. J. Cancer Clin. Oncol. 1989, 25, 123-128.
7. Petrovic, M.; Baskic, D.; Bankovic, D.; Ilic, N. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer. Biomarkers 2011, 16, 311-320.
8. Wang, Y.; Tang, D.; Sui, A.; Jiao, W.; Luo, Y.; Wang, M.; Yang, R.; Wang, Z.; Shen, Y. Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib. Clin. Transl. Oncol. 2013, 15, 384-390.
9. Nagele, F.; Petru, E.; Medl, M.; Kainz, C.; Graf, A.H.; Sevelda, P. Preoperative CA 125: An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995, 86, 259-264.
10. Bast, R.C., Jr.; Badgwell, D.; Lu, Z.; Marquez, R.; Rosen, D.; Liu, J.; Baggerly, K.A.; Atkinson, E.N.; Skates, S.; Zhang, Z.; et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 2005, 15, 274-281.
11. Cedres, S.; Nunez, I.; Longo, M.; Martinez, P.; Checa, E.; Torrejón, D.; Felip, E. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin. Lung Cancer 2011, 12, 172-179.
12. Kato, H.; Morioka, H.; Tsutsui, H.; Aramaki, S.; Torigoe, T. Value of tumor-antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 1982, 50, 1294-1296.
13. Kagohashi, K.; Satoh, H.; Ishikawa, H.; Ohtsuka, M.; Sekizawa, K. A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer. Med. Oncol. 2008, 25, 187-189.
14. Niklinski, J.; Furman, M.; Laudanski, J.; Kozlowski, M. Evaluation of squamous cell carcinoma antigen (SCC-Ag) in the diagnosis and follow-up of patients with non-small cell lung carcinoma. Neoplasma 1992, 39, 279-282.
15. Moro, D.; Villemain, D.; Vuillez, J.P.; Delord, C.A.; Brambilla, C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 1995, 13, 169-176.
16. Schneider, J.; Philipp, M.; Salewski, L.; Velcovsky, H.G. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Clin. Lab. 2003, 49, 35-42.
17. Pujol, J.L.; Quantin, X.; Jacot, W.; Boher, J.M.; Grenier, J.; Lamy, P.J. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003, 39, 131-138.
18. Pujol, J.L.; Boher, J.M.; Grenier, J.; Quantin, X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: Prospective study in 621 patients. Lung Cancer 2001, 31, 221-231.
19. Barlesi, F.; Gimenez, C.; Torre, J.P.; Doddoli, C.; Mancini, J.; Greillier, L.; Roux, F.; Kleisbauer, J.P. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir. Med. 2004, 98, 357-362.
20. Nisman, B.; Heching, N.; Biran, H.; Barak, V.; Peretz, T. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour. Biol. 2006, 27, 8-16.
21. Jacot, W.; Quantin, X.; Boher, J.M.; Andre, F.; Moreau, L.; Gainet, M.; Depierre, A.; Quoix, E.; Chevalier T.L.; Pujol, J.L. Association d'Enseignement et de Recherche des Internes en Oncologie. Brain metastases at the time of presentation of non-small cell lung cancer: A multi-centric AERIO analysis of prognostic factors. Br. J. Cancer 2001, 84, 903-909.
22. Reinmuth, N.; Brandt, B.; Semik, M.; et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002, 36, 265-270.
23. Diez, M.; Torres, A.; Maestro, M.L.; Ortega, M.D.; Gómez, A.; Pollán, M.; Lopez, J.A.; Picardo, A.; Hernando, F.; Balibrea, J.L. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br. J. Cancer 1996, 73, 1248-1254.
24. Diez, M.; Gomez, A.; Hernando, F.; Ortega, M.D.; Gómez, A.; Pollán, M.; Lopez, J.A.; Picardo, A.; Hernando, F.; Balibrea, J.L. Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer. Int. J. Biol. Markers 1995, 10, 5-10.
25. Hatzakis, K.D.; Froudarakis, M.E.; Bouros, D.; Tzanakis, N.; Karkavitsas, N.; Siafakas, N.M. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002, 69, 25-29.
26. Gaspar, M.J.; Diez, M.; Rodriguez, A.; Ratia, T.; Martin, D.A.; Galvan, M.; Granell, J.; Coca, C. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. Anticancer Res. 2003, 23, 3427-3432.
27. Nuñez, G.R.; Ito, C.; Del Giglio, A. Increased serum CA-125 levels in patients with lung cancer post thoracotomy. South Med. J. 2009, 102, 427-428.
28. Foa, P.; Fornier, M.; Miceli, R.; Seregni, E.; Santambrogio, L.; Nosotti, M.; Massaron, S.; Cataldo, I.; Oldani, S.; Iurlo, A.; et al. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int. J. Biol. Markers 1999, 14, 92-98.
29. Mizuguchi, S.; Nishiyama, N.; Iwata, T.; Nishida, T.; Izumi, N.; Tsukioka, T.; Inoue, K.; Uenishi, T.; Wakasa, K.; Suehiro, S. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer 2007, 58, 369-375.
30. Foa, P.; Fornier, M.; Miceli, R.; Seregni, E.; Santambrogio, L.; Nosotti, M.; Cataldo, I.; Sala, M.; Caldiera, S.; Bombardieri, E. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res. 1999, 19, 3613-3618.
31. Li, X.; Asmitananda, T.; Gao, L.; Seregni, E.; Santambrogio, L.; Nosotti, M.; Cataldo, I.; Sala, M.; Caldiera, S.; Bombardieri, E. Biomarkers in the lung cancer diagnosis: A clinical perspective. Neoplasma 2012, 59, 500-507.
32. Chiu, C.H.; Shih, Y.N.; Tsai, C.M.; Liou, J.L.; Chen, Y.M.; Perng, R.P. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer 2007, 57, 213-221.
33. Ma, S.; Shen, L.; Qian, N.; Chen, K. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited. Cancer Biomark. 2011-2012, 10, 155-162.
34. Tomita, M.; Shimizu, T.; Ayabe, T.; Onitsuka, T. Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer. Asia Pac. J. Clin. Oncol. 2012, 8, 244-247.
35. Grunnet, M.; Sorensen, J.B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012, 76, 138-143.
36. Cho, W.C. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed. Pharmacother. 2007, 61, 515-519.